Actionable news
All posts from Actionable news
Actionable news in GUID: Guidance Software, Inc.,

Top Analyst Upgrades and Downgrades: AstraZeneca, Hasbro, Roche, Peabody Energy, Suncor, Wynn and More

The futures traded higher Wednesday morning as the market started to look to the first-quarter earnings reports that are set to begin. Most of the pundits on Wall Street are fairly positive about the economy and how the top companies will do when reporting. One thing seems likely with the market still trading within reach of all-time highs: any company that misses estimates or gives poor forward guidance could be in trouble

24/7 Wall St. reviews dozens of analyst research reports each morning to find new trading and investing ideas for its readers. Some analyst calls cover stocks to buy, while others cover stocks to sell or avoid.

These are this Wednesday’s top analyst upgrades, downgrades and initiations.

AstraZeneca PLC (NYSE: AZN) was downgraded to Neutral from Buy at UBS. The 52-week trading range for the stock is $25.55 to $35.44, and the Wall Street consensus price target is $33.87. The shares closed trading on Tuesday at $31.28.

Blueprint Medicines Corp. (NASDAQ: BPMC) saw its price target raised to $50 from $43 at Wedbush. The Wedbush report cited BLU-667’s updated development status, as well as additional model tweaks that include the closing of the company’s recent equity financing that raised net proceeds of $215.6 million. The 52-week trading range is $13.27 to $44.54, and the consensus price target is $45.71. The shares closed on Tuesday at $41.98, up almost 5% on the day.

Duke Realty Corp. (NYSE: DRE) was raised to Buy from Neutral at Merrill Lynch. The 52-week range is $21.11 to $28.99, and the consensus price target is set at $27.77. The stock closed Tuesday at $26.68.

Hasbro Inc. (NYSE: HAS) saw its price target raised from $90 to $95 at...